These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

545 related items for PubMed ID: 18376330

  • 1. Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
    Stanković Z, Britvić D, Vuković O, Ille T.
    Psychiatr Danub; 2008 Mar; 20(1):42-52. PubMed ID: 18376330
    [Abstract] [Full Text] [Related]

  • 2. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 3. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D, Delgado A, Bouju S, Comet D, Chiariny JF.
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [Abstract] [Full Text] [Related]

  • 4. Adherence to depot versus oral antipsychotic medication in schizophrenic patients during the long-term therapy.
    Stanković Z, Ille T.
    Vojnosanit Pregl; 2013 Mar; 70(3):267-73. PubMed ID: 23607237
    [Abstract] [Full Text] [Related]

  • 5. [Relationships between insight and medication adherence in subjects with psychosis].
    Droulout T, Liraud F, Verdoux H.
    Encephale; 2003 Mar; 29(5):430-7. PubMed ID: 14615692
    [Abstract] [Full Text] [Related]

  • 6. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK, Zalar B, Breskvar K, Dolzan V.
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [Abstract] [Full Text] [Related]

  • 7. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD, Saleem PT, Glue P, Arnoldussen WJ, Teijeiro R, Lex A, Latif MA, Medori R.
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [Abstract] [Full Text] [Related]

  • 8. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.
    Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D, Healy D, Rae P, Power C.
    Arch Gen Psychiatry; 2005 Jul; 62(7):717-24. PubMed ID: 15997012
    [Abstract] [Full Text] [Related]

  • 9. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L, Jaffe A, Levine J.
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [Abstract] [Full Text] [Related]

  • 10. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
    Gharabawi G, Bossie C, Turkoz I, Kujawa M, Mahmoud R, Simpson G.
    J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
    [Abstract] [Full Text] [Related]

  • 11. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C, Dusouchet T, Bret P, Queuille E, Biscay ML, Caron J, Bret MC.
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [Abstract] [Full Text] [Related]

  • 12. Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication.
    Rettenbacher MA, Burns T, Kemmler G, Fleischhacker WW.
    Pharmacopsychiatry; 2004 May; 37(3):103-9. PubMed ID: 15138893
    [Abstract] [Full Text] [Related]

  • 13. Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia.
    Kim JH, Kim SY, Ahn YM, Kim YS.
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):301-5. PubMed ID: 16309807
    [Abstract] [Full Text] [Related]

  • 14. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G, Annable L, Campbell W.
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [Abstract] [Full Text] [Related]

  • 15. Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia.
    Rocca P, Crivelli B, Marino F, Mongini T, Portaleone F, Bogetto F.
    Compr Psychiatry; 2008 Aug; 49(2):170-6. PubMed ID: 18243890
    [Abstract] [Full Text] [Related]

  • 16. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia.
    Hofer A, Rettenbacher MA, Edlinger M, Kemmler G, Widschwendter CG, Fleischhacker WW.
    Acta Psychiatr Scand; 2007 Nov; 116(5):354-61. PubMed ID: 17868428
    [Abstract] [Full Text] [Related]

  • 17. [Intervals between hospitalisations in schizophrenia patients under antipsychotics in depot-form versus oral second generation antipsychotics].
    Gutwinski S, Müller P, Koller M.
    Psychiatr Prax; 2007 Sep; 34(6):289-91. PubMed ID: 17806015
    [Abstract] [Full Text] [Related]

  • 18. Clozapine maintenance therapy in schizophrenia.
    Gaszner P, Makkos Z.
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):465-9. PubMed ID: 15093952
    [Abstract] [Full Text] [Related]

  • 19. Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol.
    Kim JH, Byun HJ.
    J Clin Pharm Ther; 2007 Oct; 32(5):461-7. PubMed ID: 17875112
    [Abstract] [Full Text] [Related]

  • 20. Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets.
    Normann C, Schmauss M, Bakri N, Gerwe M, Schreiner A.
    Pharmacopsychiatry; 2006 Nov; 39(6):209-12. PubMed ID: 17124642
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.